{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:57:03Z","timestamp":1788821823130,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.cgh.2012.06.032","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T13:19:35Z","timestamp":1342617575000},"page":"1079-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"title":["Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Ingrid","family":"Ord\u00e1s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2012.06.032_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2012.06.032_bib2","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2012.06.032_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2012.06.032_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2012.06.032_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2012.06.032_bib10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2012.06.032_bib11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2012.06.032_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2012.06.032_bib13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2012.06.032_bib14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2012.06.032_bib15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2012.06.032_bib16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2012.06.032_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2012.06.032_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2012.06.032_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2012.06.032_bib20","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2012.06.032_bib21","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2012.06.032_bib22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"Wang","year":"2012","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cgh.2012.06.032_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","article-title":"Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease","volume":"34","author":"Steenholdt","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2012.06.032_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2012.06.032_bib26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2012.06.032_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development","volume":"24","author":"Mould","year":"2010","journal-title":"Biodrugs"},{"key":"10.1016\/j.cgh.2012.06.032_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"Morell","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cgh.2012.06.032_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2012.06.032_bib30","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0016-5085(12)61457-7","article-title":"Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure","volume":"142","author":"Kevans","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2012.06.032_bib32","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ard.2011.153023","article-title":"Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis","volume":"70","author":"Takeuchi","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2012.06.032_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cyto.2009.02.001","article-title":"TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis","volume":"46","author":"Olsen","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.cgh.2012.06.032_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2012.06.032_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cgh.2012.06.032_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2012.06.032_bib37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","article-title":"Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients","volume":"35","author":"Bultman","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2012.06.032_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gutjnl-2011-300370","article-title":"Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2012.06.032_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","volume":"34","author":"Nestorov","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cgh.2012.06.032_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2012.06.032_bib41","article-title":"Infliximab concentration and clinical outcome in patients with ulcerative colitis","volume":"142","author":"Reinisch","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib42","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2012.06.032_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.22910","article-title":"Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease","author":"Steenholdt","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2012.06.032_bib44","article-title":"Antibodies to infliximab can either be persistent or transient: a retrospective case-control study in IBD patients treated with infliximab maintenance therapy","volume":"142","author":"Vande Casteele","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.2010.236869","article-title":"Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment","volume":"61","author":"Vande Casteele","year":"2012","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2012.06.032_bib46","article-title":"Novel infliximab and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease","volume":"142","author":"Feagan","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2012.06.032_bib47","article-title":"Certolizumab pegol plasma concentration and clinical remission in Crohn's disease","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2012.06.032_bib48","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0016-5085(12)60792-6","article-title":"Results on the optimisation phase of the prospective controlled Trough Level Adapted Infliximab Treatment (TAXIT) trial","volume":"142","author":"Vande Casteele","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2012.06.032_bib49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356512007987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356512007987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:09:53Z","timestamp":1761541793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356512007987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1542356512007987"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2012.06.032","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2012.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}